MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health EPS Ratio 2011-2026 | OPK
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | -0.09 | -0.46 | -0.05 | 0.05 | -0.53 | -0.27 | -0.55 | -0.09 | -0.11 | -0.41 | -0.32 | -0.11 | -0.01 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.05 | -0.55 | -0.209 |
Quarterly EPS Ratio OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.19 | -0.1 | 0.04 | -0.01 | -0.12 | -0.11 | -0.03 | -0.02 | - | -0.11 | -0.14 | -0.08 | -0.11 | 0.04 | -0.03 | 0.05 | 0.05 | 0.04 | 0.05 | -0.09 | -0.18 | -0.11 | -0.1 | -0.14 | -0.13 | -0.05 | -0.01 | -0.08 | -0.39 | -0.06 | -0.03 | -0.06 | -0.04 | -0.04 | 0.02 | -0.03 | - | 0.26 | -0.09 | -0.26 | -0.12 | -0.11 | -0.06 | -0.11 | -0.04 | -0.17 | -0.01 | -0.11 | - | -0.03 | -0.04 | -0.03 | 0.06 | -0.03 | -0.02 | -0.02 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.26 | -0.39 | -0.0609 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
-2.16 | $ 2.13 | -2.74 % | $ 4.89 M |  USA |
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M |  Israel |
 |
Castle Biosciences
CSTL
|
0.66 | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
8.87 | $ 195.6 | 0.17 % | $ 21.7 B | USA |
 |
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-0.23 | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
2.14 | $ 65.94 | -1.51 % | $ 25.7 B | USA |
 |
Co-Diagnostics
CODX
|
-1.2 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-1.1 | $ 104.91 | - | $ 19.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-1.41 | $ 16.33 | 5.29 % | $ 494 M | USA |
 |
Charles River Laboratories International
CRL
|
-2.91 | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
7.91 | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
-13.2 | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-4.85 | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Interpace Biosciences
IDXG
|
1.42 | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
13.2 | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Agilent Technologies
A
|
3.98 | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
Illumina
ILMN
|
-7.69 | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
ICON Public Limited Company
ICLR
|
9.6 | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
DarioHealth Corp.
DRIO
|
10.1 | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
-3.32 | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
0.38 | - | - | $ 10.6 B |  Niderland |
 |
CareDx, Inc
CDNA
|
-0.4 | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
Lantheus Holdings
LNTH
|
3.46 | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Celcuity
CELC
|
-2.83 | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Medpace Holdings
MEDP
|
15.6 | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
10.5 | $ 264.42 | 0.54 % | $ 22 B | USA |
 |
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
42.2 | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-3.95 | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.55 | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
-0.84 | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
National Research Corporation
NRC
|
50 | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
-5.57 | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
-1.82 | $ 1.39 | 4.51 % | $ 417 M | USA |
 |
RadNet
RDNT
|
-0.25 | $ 61.74 | 0.41 % | $ 4.64 B | USA |
 |
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | USA |